Recent Publications

Recent publications on Mucosis’ technology and vaccine programs are listed below.

Mimopath-Based Vaccine Delivery. K. Leenhouts. 2013. In: Novel Immune Potentiators and Delivery Technologies for Next Generation Vaccines (ed. M. Singh), pp. 245-265. Springer, New York.

Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration. A. de Haan, B.J. Haijema, P. Voorn, T. Meijerhof, M.L. van Roosmalen, K. Leenhouts. Vaccine 30 (2012):4884-4891.

Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant. V. Saluja, J.P. Amorij, M.L. van Roosmalen, K. Leenhouts, A. Huckriede, W.L.J. Hinrichs, H.W. Frijlink. AAPS J. 12 (2010):109-116.

Gastro-intestinal delivery of influenza subunit vaccine formulation adjuvanted with Gram-positive Enhancer Matrix (GEM) particles. V. Saluja, M.R. Visser, M.L. van Roosmalen, K. Leenhouts, A. Huckriede, W.L.J. Hinrichs, H.W. Frijlink. Eur. J. Pharm. Biopharm. 76 (2010):470-474.

Bacterium-like particles as multi-epitope delivery platform for Plasmodium berghei circumsporozoite protein induce complete protection against malaria in mice. K. Nganou-Makamdop, M.L. van Roosmalen, S.A. Audouy, G.J. van Gemert, K. Leenhouts, C.C. Hermsen, R.W. Sauerwein. Malaria J. 11 (2012):50.

Neonatal mucosal immunization with a non-living, non-genetically modified Lactococcus lactis vaccine carrier induces systemic and local Th1-type immunity and protects against lethal bacterial infection. K. Ramirez , Y. Ditamo, L. Rodriguez, W.L. Picking, M.L. van Roosmalen, K. Leenhouts, M.F. Pasetti. Mucosal Immunol. 3 (2010):159-171.

Development of lactococcal GEM-based pneumococcal vaccines. S.A.L. Audouy, S. van Selm, M.L. van Roosmalen, E. Post, R. Kanninga, J. Neef, S. Estevão, E.E.S. Nieuwenhuis, P.V. Adrian, K. Leenhouts, P.W.M. Hermans. Vaccine 25 (2007):2497-2506.

Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria. M.L. van Roosmalen, R. Kanninga, M. El Khattabi, J. Neef, S. Audouy, T. Bosma, A. Kuipers, E. Post, A. Steen, J. Kok, G. Buist, O.P. Kuipers, G. Robillard, K. Leenhouts. Methods 38 (2006):144-149.

read more >

16.05.13 Mucosis presents preclinical data demonstrating protection by its intranasal SynGEM® RSV vaccine candidate
more >

08.10.12 Mucosis signs Research and License Option Agreement with Crucell
more >

25.09.12 ExpreS²ion, Mucosis, and University of Copenhagen receive Eurostars grant
more >

18.09.12 Mucosis Appoints Thomas Johnston to CEO
more >

10.05.12 Mucosis announces positive proof-of-concept data for Mimopath® platform in humans
more >

03.05.12 Mucosis announces publication of preclinical data demonstrating...
more >

15.11.11 Mucosis announces new scientific advisory board
more >

17.05.11 Mucosis appoints Thomas Johnston as Chief Business Officer
more >